Immune Factors and Natural Killer Cells in Recurrent Loss

Because pregnancy involves maternal tolerance of a semi-allogeneic fetus, immune dysfunction has long been proposed as a cause of recurrent loss, with uterine natural killer cells a particular focus. This entry surveys the immunological hypotheses, the distinction between uterine and peripheral natural killer cells, and the substantial uncertainty and controversy that surround immune testing and immunotherapy in this setting.

Definition

Immune factors in recurrent loss refer to proposed disturbances in maternal-fetal immune tolerance, including altered numbers or activity of natural killer cells at the maternal-fetal interface or in peripheral blood, advanced as contributors to repeated pregnancy loss; their causal role remains unproven.

Scope

The entry covers the concept of maternal-fetal immune tolerance, the biology and proposed roles of uterine versus peripheral blood natural killer cells, the alloimmune and autoimmune hypotheses of recurrent loss, and the contested status of immune testing and immunotherapies. It is a reference orientation and does not endorse any diagnostic test or treatment.

Core questions

• How does the maternal immune system tolerate the semi-allogeneic fetus?
• How do uterine natural killer cells differ from peripheral blood natural killer cells?
• Is altered natural killer cell number or activity causally linked to recurrent loss?
• What is the status of immune testing and immunotherapy in recurrent loss?

Key concepts

• Maternal-fetal immune tolerance
• Uterine natural killer cells
• Peripheral blood natural killer cells
• Alloimmune hypothesis
• Cytokine balance
• Immunotherapy controversy

Mechanisms

At the maternal-fetal interface, specialized uterine natural killer cells are abundant in early pregnancy and are thought to support spiral-artery remodelling and trophoblast invasion rather than to attack the fetus, distinguishing them from cytotoxic peripheral blood natural killer cells. Immunological hypotheses of recurrent loss propose that disturbed tolerance, abnormal natural killer cell number or activity, or skewed cytokine profiles impair implantation or placentation. However, peripheral blood natural killer cells do not reliably reflect uterine populations, and the evidence linking measured immune parameters to loss is inconsistent.

Clinical relevance

Immune explanations are attractive to patients with otherwise unexplained recurrent loss, which has fostered widespread offering of immune tests and therapies despite weak evidence. This entry summarizes the biology and the evidentiary debate for reference; it does not recommend immune testing or immunotherapy, which guidelines generally do not support outside research.

Epidemiology

A large share of recurrent loss is unexplained after standard evaluation, and immune causes are hypothesized to account for some of these cases, but the proportion truly attributable to immune dysfunction is unknown given measurement and definitional difficulties.

Evidence & guidelines

A systematic review and meta-analysis examined natural killer cell levels in women with recurrent miscarriage and infertility, finding associations that are limited by heterogeneity and uncertain clinical meaning. Major guidelines, including ESHRE, do not recommend routine natural killer cell testing or immunotherapies such as intravenous immunoglobulin for recurrent loss outside a research context.

History

Reproductive immunology grew from the puzzle of how the maternal immune system tolerates the fetus, generating alloimmune theories of recurrent loss and a range of immunotherapies in the late twentieth century. Many of these treatments were later found ineffective or harmful in trials, and attention shifted to characterizing uterine natural killer cells and to distinguishing them from peripheral blood populations, while emphasizing the gap between association and causation.

Debates

Do peripheral blood natural killer cell tests inform recurrent loss?

Peripheral blood natural killer cells differ from uterine natural killer cells and have uncertain relevance to pregnancy outcome, so the value of testing them is widely questioned.

Is immunotherapy justified for recurrent loss?

Immunotherapies have largely failed to show benefit in controlled studies, and guidelines advise against their routine use outside research.

Key figures

• Ashley Moffett
• Siobhan Quenby
• Ole Bjarne Christiansen

Seminal works

• seshadri-nk-2014
• rai-regan-2006

Frequently asked questions

Are natural killer cells a proven cause of recurrent miscarriage?

No. Associations have been reported, but uterine and blood natural killer cells differ and the evidence does not establish them as a proven, treatable cause; routine testing is not recommended by major guidelines.

Should immune treatments be used for recurrent loss?

Major guidelines do not recommend immunotherapies for recurrent loss outside research, because controlled studies have generally not shown benefit.